drugset / Trial / NCT01059552
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
18 enrolled
Fox Chase Cancer Center
National Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
Timeline
- Start
- 2009-12-16
- Primary completion
- 2015-07-22
- Completion
- 2019-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | — | — |